Report top-line results of the SARA-INT Phase 2 sarcopenia trial
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 26 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- October 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Biophytis expects to report top-line data from SARA-INT in Q2 2021, subject to any delays in patient recruitment or retention”
What we found
Evidence strength A What the grades mean
On June 30, 2021 the company said topline results would be released in August 2021. The 2022 20-F states the topline data was published in October 2021, after the Q2 2021 deadline.
-
A Biophytis S.A. 6-K filed 2021-07-01
“today announces topline results for SARA-INT phase 2 study will be released in August 2021.” ✓ confirmed on the page
-
A Biophytis S.A. 20-F filed 2022-04-21
“The topline data for our SARA-INT Phase 2b clinical trial was published in October 2021.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Top-line results of SARA-INT Phase 2 trial
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: subject to delays in patient recruitment or retention, supply chain, regulatory authorizations, and COVID-19-related delays
- Depends on
- Regulatory, Supplier
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Biophytis S.A.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C768946-024741 · Corrections policy